Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PSTI

Pluristem Therapeutics (PSTI) Stock Price, News & Analysis

Pluristem Therapeutics logo

About Pluristem Therapeutics Stock (NASDAQ:PSTI)

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$1.58
52-Week Range
N/A
Volume
2,128 shs
Average Volume
715,259 shs
Market Capitalization
$32.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Receive PSTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTI Stock News Headlines

NBRVF Nabriva Therapeutics plc
Pluri CEO Issues Shareholder Update
Shocking footage from Bill Gates’ $100,000,000,000 AI Bet
If you missed out on Nvidia, watch this video I just made.
See More Headlines

PSTI Stock Analysis - Frequently Asked Questions

Pluristem Therapeutics Inc. (NASDAQ:PSTI) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.05.

Pluristem Therapeutics shares reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pluristem Therapeutics investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Meta Platforms (META), Gilead Sciences (GILD), Novavax (NVAX) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/08/2021
Today
11/23/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PSTI
Employees
153
Year Founded
2003

Profitability

Net Income
$-49,870,000.00
Pretax Margin
-20,024.79%

Debt

Sales & Book Value

Annual Sales
$20,000.00
Book Value
$1.80 per share

Miscellaneous

Free Float
30,601,000
Market Cap
$32.35 million
Optionable
Optionable
Beta
1.91

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:PSTI) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners